Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trevi TherapeuticsTRVI -3.08%22 Pretax Margin % is % as of Jun. 2026. GuruFocus rates TRVI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Trevi Therapeutics ranks worse than 105932.1% on this metric.
The historical rank and industry rank for Trevi Therapeutics's Pretax Margin % or its related term are showing as below:
TRVI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.365 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Trevi Therapeutics Pretax Margin % Related Terms
Trevi Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Trevi Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRVI vs IMNM, VERA, NRIX: Pretax Margin % Comparison
For the Biotechnology subindustry, Trevi Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trevi Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Trevi Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trevi Therapeutics (TRVI) has a Pretax Margin % of % as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Trevi Therapeutics and its competitors. According to the industry distribution chart, Trevi Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is Trevi Therapeutics' Pretax Margin % too high?
Trevi Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Trevi Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Trevi Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Trevi Therapeutics' Pretax Margin % compare to IMNM and VERA?
According to the Biotechnology industry distribution chart, Trevi Therapeutics ranks #999999 out of 944 companies for Pretax Margin %. This places Trevi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Trevi Therapeutics and its competitors. Trevi Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trevi Therapeutics stock overvalued right now?
Trevi Therapeutics (TRVI) has a current Pretax Margin % of %. The current Pretax Margin % is %. Trevi Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Trevi Therapeutics (TRVI), the current Pretax Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
22GF Score
Get the complete analysis for TRVI
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRVI has been successfully added to your 
